Clinical Trial Update: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 2]

View source ↗

Summary

Phase 2 study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in relapsed/refractory indolent non-Hodgkin's lymphoma; study completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Tenalisib (tenalisib)

Snippet

Sponsor: Rhizen Pharmaceuticals SA | Conditions: Non Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-12